T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
about
Novel technologies and emerging biomarkers for personalized cancer immunotherapyIntegrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of ImmunotherapyTherapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advancesImmunological effect of local ablation combined with immunotherapy on solid malignancies.Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implicationsClinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels.Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survivalPD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancerAdding fuel to the fire: immunogenic intensification.Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis.Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?Perspectives on treatment of metastatic castration-resistant prostate cancer.Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapyMonitoring regulatory immune responses in tumor immunotherapy clinical trials.Understanding the biology of antigen cross-presentation for the design of vaccines against cancer.Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.Immunotherapy in prostate cancer: challenges and opportunities.Immunogenomics: using genomics to personalize cancer immunotherapy.PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.Immunotherapy for prostate cancer: False promises or true hope?Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cellsMyeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination.Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment.Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning.Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200.Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types.
P2860
Q26770780-18F690A0-CDCA-4657-9A68-55E142E2850CQ26783783-E20ADA79-4B94-4C05-9B43-CCE0F2C965B3Q26827475-4DCD135B-211D-4B92-BA2B-4BAAE7601A6CQ30354580-C71D5E65-E6BB-4631-8160-2FD5196F93FEQ33621393-21F56903-E4BA-44DF-AB12-1DC52890FF98Q33657979-458532B9-90ED-46E1-9B78-5769BEFE29AEQ33688931-BC448C48-DAC4-41BC-80B1-8E5362FFBE7FQ34353251-5505396B-3910-4837-9223-9C17D62B4AB6Q35713307-A8988520-A460-4C23-924F-9F2C2243FF64Q35886393-69631690-A879-4BF5-A0CF-5E3F532FEF77Q36020800-FAF0810F-C51D-4D1C-8EBD-AC43CFCC26EEQ36283876-DC914433-7523-48ED-A56E-0AB6AB982B5FQ36804897-2ADE751B-50CF-4E4E-9BCA-5100CF23CD23Q36871685-5DD236B5-A2C7-4D3A-989C-877623A1BE43Q37014134-3BFFDE65-3BFB-40AD-B253-1D78A7E96CAEQ37369239-42CBBCD8-4451-4400-B069-F7AC530B684CQ37652790-5454873D-9BF8-48E4-860C-44BD08D938CEQ38105081-95B03949-C624-42FE-97ED-690FBACE6FDCQ38208305-1AADCF09-B3E5-4762-91FC-41190251CEA9Q38212231-42F3E516-531D-46D8-85BB-72AD2CE92C81Q38447992-1F140DFE-E05B-4CB9-BCB1-0369D2DB5081Q38600417-312866FD-48AE-4426-950D-ED44CF566D30Q38661079-64E5B1B8-3C77-4789-9BAD-C522DFC836B0Q38772744-37A6C4AE-DB68-4444-A18B-3DC499F439B5Q38937417-0428DF7D-A9BA-4736-883B-C72F69E59B62Q38959645-B691DCD3-57B6-43B8-A832-236C203DC093Q39069273-FDC1D41D-65B0-4E6B-97C8-79033691E216Q39084400-53C6203D-94A8-4217-9B09-D878DE9D7ADBQ40437042-C8134D85-5A2D-4615-A152-50C59E8AB222Q40713858-74A059EF-411B-4FA2-8885-62B3777862AAQ41041538-89A2DB04-AB0C-4C54-9517-ECC4E671A4BBQ41557983-E06087AB-3268-40BC-81BA-386A1B5DA239Q42549680-C90CC237-8386-4169-94FD-BED12F8D29F4Q42755227-88652DF1-37C6-4CEF-B523-1639D55F1EE7Q46971015-E00E596C-CBB3-4E14-9634-A608260AB5EDQ47141309-E73A3BA3-CEB8-4134-BF5E-40CECDFE6F6CQ54511300-045B8A7B-DDDA-4BDD-806E-E918CCF06888
P2860
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
T cell profiling reveals high ...... ate GVAX/ipilimumab treatment.
@en
T cell profiling reveals high ...... ate GVAX/ipilimumab treatment.
@nl
type
label
T cell profiling reveals high ...... ate GVAX/ipilimumab treatment.
@en
T cell profiling reveals high ...... ate GVAX/ipilimumab treatment.
@nl
prefLabel
T cell profiling reveals high ...... ate GVAX/ipilimumab treatment.
@en
T cell profiling reveals high ...... ate GVAX/ipilimumab treatment.
@nl
P2093
P2860
P1476
T cell profiling reveals high ...... ate GVAX/ipilimumab treatment.
@en
P2093
Alfons J M van den Eertwegh
Anita G M Stam
B Mary E von Blomberg
Helen Gall
Israel Lowy
Jean-Marie Cuillerot
Karin Jooss
Kristen Hege
Martine Reijm
Natalie Sacks
P2860
P2888
P304
P356
10.1007/S00262-012-1330-5
P577
2012-08-10T00:00:00Z